Overall, the study presented here identifies PTEN inactivation as an oncogenic event in immature murine thymic T cell lymphomas with ATM deficiency and highlights AKT as a potential molecular target for therapy in human T-ALL/T-LBL. This evidence concerns the gene PTEN and acute lymphoblastic leukemia.